Accelr8 Technology Corporation to Trade on Amex

    DENVER, Oct. 3 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation
 (OTC Bulletin Board:   ACLY) announced today that its shares are expected to
 begin trading on the American Stock Exchange on or about October 9, 2003.  Its
 new trading symbol will be (Amex:   AXK).
     Accelr8 sells advanced microarray slides and specialty microtiter plates
 coated with its proprietary OptiChem(TM) activated surface chemistry.  This
 surface has the extraordinary ability to eliminate unwanted background noise
 from bio-analytical performance by enabling higher sensitivity, greater
 reproducibility, and higher throughput by making it possible to eliminate
 processing steps such as protein blocking.
 
     Accelr8 Technology's vision is to compete in the general area of
 biosciences, including DNA/RNA assays, protein-based assays and biosensors.
 Accelr8's proprietary surface chemistry and its quantification instruments
 support real-time assessment of medical diagnostics, food borne pathogens,
 water borne pathogens and bio-warfare assessments.
 
     Certain statements in this news release may be "forward-looking
 statements" within the meaning of Section 27A of the Securities Act of 1933,
 as amended, and Section 21E of the Securities Exchange Act of 1934, as
 amended.  Statements regarding future prospects and developments are based
 upon current expectations and involve certain risks and uncertainties that
 could cause actual results and developments to differ materially from the
 forward-looking statement, including those detailed in the company's filings
 with the Securities and Exchange Commission.
 
 

SOURCE Accelr8 Technology Corporation

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.